Pharmaceuticals & Healthcare – Global Q418 Round-Up #Fitch_SolutionsJanuary 12, 2019
There will be a gradual rise in the use of pharmaceutical tenders globally, and manufacturers will increasingly compete to offer the lowest price for the medicines.
In November 2018, the Association of the British Pharmaceutical Industry (ABPI) announced that a deal had been reached between the UK’s National Health Service (NHS) and the pharmaceutical industry on the 2019 Pharmaceutical Price Regulation Scheme (PPRS).
According to the Deputy Head of Economics and Analysis of the Pharmaceutical Industry for the Russian Ministry of Industry and Trade, the share of domestically-produced medicines continues to increase due to Russia’s localisation policies, with the share of vital and essential drugs reaching over 84% for example.
Under the ACA, which the Republican Party had tried to ‘repeal and replace’, insurers could no longer deny coverage to consumers or charge them more because of their health backgrounds.
The government announced plans to cut funds to half of its ministries, and one of those affected is the Ministry of Health.
The Ministry of Health will develop a digital system to store medical information collected from the database of households joining the country’s health insurance regime.
It is hoped that reducing corporate tax will improve the competitiveness of domestic businesses and make Tunisia a more attractive investment destination.
Under the terms of the agreement, Julphar will initially manufacture and supply three of BIOCAD’s cancer treatments, which will be launched in the UAE through partnerships with local health authorities.
In October 2018, a number of South African pharmaceutical manufacturers lobbied the Department of Health (DoH) to adjust the single exit price (SEP) rates in line with drug production costs and inflation rates.
BMI and FSG are both affiliates of Fitch Ratings Inc. (‘Fitch’).
In 1952 researchers at Ciba discovered the first orally available vasodilator, hydralazine. A major shortcoming of hydralazine monotherapy was that it lost its effectiveness over time (tachyphylaxis). In the mid-1950s Karl H. Beyer, James M. Sprague, John E. Baer, and Frederick C. Novello of Merck and Co. discovered and developed chlorothiazide, which remains the most widely used antihypertensive drug today. This …